Abstract:The protease beta-secretase plays a critical role in the synthesis of pathogenic amyloid-beta in Alzheimer's disease. In this study, pharmacophore constructed from receptor-ligand complex was used to screen Chemdiv and Zinc database and the resulting hits were subjected to docking experiments using LiandFit and CDOCKER programs. Molecules with high consensus scores and good interaction patterns in docking programs were retained. Drug-likeness assay including Lipinski's rule of five and ADMET properties filters were further used to identify BACE1 inhibitor. Finally, 13 compounds with novel scaffolds were selected and, considering of the nature of relative high LogP value of many marketed AD drugs, three of them with top 3 predicted LogP value were evaluated for their IC50 values in vitro by BACE1 enzymatic activity study. We believe that compound 13 with an IC50 value of 136 mu M can be a lead compound with great potential in BACE1 inhibition and increasing activity by subsequently structure modification or optimization. At the same time, we found that the interaction between the residues Asp228, Asp32 of BACE1 and ligands is significant through analyzing the binding mode of 13 candidate compounds.

Design and Synthesis of Benzimidamides As Potential BACE1 Inhibitors

Design and Synthesis of 2-Aminobenzimidazoles As Potential BACE1 Inhibitors

Design, Synthesis and Evaluation of 3-(2-aminoheterocycle)-4-benzyloxyphenylbenzamide Derivatives As BACE-1 Inhibitors

Design, Synthesis and in Vitro Biological Evaluation of 3- Styrylbenzimidamides As Potential BACE1 Inhibitors

Synthesis, in vitro biological evaluation and molecular docking studies of benzimidamides as potential BACE1 inhibitors.

Identification of pharmacophore model, synthesis and biological evaluation of N-phenyl-1-arylamide and N-phenylbenzenesulfonamide derivatives as BACE 1 inhibitors.

Design, synthesis, and in vitro activity of methylisoxazole/isothiazole amides as BACE1 inhibitors

2-Substituted-thio-n-(4-substituted-thiazol/1h-imidazol-2-yl)acetamides As BACE1 Inhibitors: Synthesis, Biological Evaluation and Docking Studies.

Dual-target-directed 1,3-Diphenylurea Derivatives: BACE 1 Inhibitor and Metal Chelator Against Alzheimer’s Disease

Progress in the Development of Nonpeptidomimetic BACE 1 Inhibitors for Alzheimers Disease

Identification Of Novel Bace1 Inhibitors By Combination Of Pharmacophore Modeling, Structure-Based Design And In Vitro Assay

Design, Synthesis, and Bioevaluation of Benzamides: Novel Acetylcholinesterase Inhibitors with Multi-Functions on Butylcholinesterase, Aβ Aggregation, and Β-Secretase.

4-Oxo-1,4-dihydro-quinoline-3-carboxamides as BACE-1 inhibitors: synthesis, biological evaluation and docking studies.

Design, synthesis and biological evaluation of tasiamide B derivatives as BACE1 inhibitors.

Discovery of potent iminoheterocycle BACE1 inhibitors

Searching for the Multi-Target-Directed Ligands Against Alzheimer’s Disease: Discovery of Quinoxaline-Based Hybrid Compounds with AChE, H3R and BACE 1 Inhibitory Activities

Multipotent Ache and Bace-1 Inhibitors for the Treatment of Alzheimer'S Disease: Design, Synthesis and Bio-Analysis of 7-Amino-1,4-dihydro-2h-isoquilin-3-one Derivates

Structure-based design and synthesis of novel P2/P3 modified, non-peptidic β-secretase (BACE-1) inhibitors

Structure-based design and synthesis of novel P2/P3 modified, non-peptidic beta-secretase (BACE-1) inhibitors.

Discovery and optimization of a novel spiropyrrolidine inhibitor of β-secretase (BACE1) through fragment-based drug design.

Synthesis and Preliminary Evaluation of Peptidomimetic Inhibitors of Human Beta-Secretase